Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
Ryan S. Thwaites(University of Oxford), Tom Solomon(University of Liverpool), Yanick J. Crow(Institute of Genetics and Cancer), Felicity Liew(Imperial College London), Christopher Chiu(Imperial College London), David Hunt(Mott MacDonald (United Kingdom)), Julian A. Hiscox(University of Liverpool), Stephanie Ascough(Imperial College London), Debby Bogaert(MRC Centre for Regenerative Medicine), Tom Fletcher, Matthew K. Siggins(Lung Institute), Paul Klenerman(John Radcliffe Hospital), J. Kenneth Baillie(NHS Lothian), William Barclay(Imperial Valley College), Cameron J. Fairfield(Imperial College London), Saye Khoo(University of Liverpool), Beatrice Alex(Imperial College London), Benjamin Bach(University of Edinburgh), Graham P. Taylor(NIHR Imperial Biomedical Research Centre), Peter Horby, Malcolm G. Semple(University of Liverpool), Antonia Ho(University of Glasgow), Simon T. Abrams(University of Liverpool), Ana da Silva Filipe(MRC University of Glasgow Centre for Virus Research), Meera Chand(St Thomas' Hospital), Ashley Sanchez Sevilla Uruchurtu(Lung Institute), Thilipan Thaventhiran(Imperial College London), Jake Dunning(University of Oxford), Rishi K Gupta, Samreen Ijaz(Environment Agency), Clark D Russell(Centre for Inflammation Research), Lance Turtle(University of Liverpool), Charlotte‐Eve Short(Imperial College London), Christopher Green(UCSF Helen Diller Family Comprehensive Cancer Center), Emma Bergstrom(MRC Centre for Regenerative Medicine), G Cooke, Edwin Carter(Edinburgh Cancer Research), Zoe Gardener(Edinburgh Cancer Research)
Cited by 259
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
An atlas of active enhancers across human cell types and tissues
|Nature|2014|2.8k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k